Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  11:35 2022-09-23 am EDT
10016.00 GBX   +0.83%
01:26aTalks on second-gen COVID vaccine will take months and could fail, Valneva warns
RE
12:21aAstraZeneca Junks Ionis' Cholesterol Drug After Failing To Reach Efficacy Threshold In Phase 2 Study
MT
09/23ADRs End Lower, Alibaba and AstraZeneca Trade Actively
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Australia biotech giant CSL reports profit dip, flags cost spiral

08/16/2022 | 07:28pm EDT

Aug 17 (Reuters) - Australian biotech giant CSL Ltd said annual profit fell due to declining donations of blood plasma, the key ingredient of its products, and flagged higher staffing costs as collection volumes returned to pre-pandemic levels.

Australia's third-largest company makes most of its money paying people in the United States for blood plasma which it converts to treatments for rare diseases, but since the onset of COVID-19 in 2020 it has experienced a slump in donations because of movement restrictions and health concerns.

That resulted in a 6% dip in year-to-June profit to $2.24 billion, in line with the company's guidance. The former government laboratory said donations rebounded by a quarter since it raised the fees it pays, setting it up for stronger sales, but added that rising costs would constrain profit margins.

"Costs are up, employee costs are up, the amount of people (available) to work, especially in the retail sector, is very tight," CEO Paul Perreault said on a media call.

Wages at its more than 300 collection centres were up as much as 10%, which Perreault called "a signfiant increase to compete".

The update shows how raging inflation is impacting the top tier of the Australian economy. CSL shares were down 4% by mid-session, against a flat overall market, as analysts recalculated forecasts to include the changed operating environment.

"Higher cost of plasma is expected to continue," Jefferies analysts said in a client note, which also noted profit margins from CSL's blood plasma sales had thinned more than expected.

Offsetting the profit decline, CSL's vaccine business, which brings a sixth of profit, grew its contribution 16% as the pandemic stoked demand for inoculations against COVID-19 and other viruses like influenza.

CSL said it expected net profit in fiscal 2023 between $2.4 billion and $2.5 billion and declared a final dividend of $1.18 per share, unchanged from last year.

(Reporting by Byron Kaye in Sydney and Roushni Nair and Jaskiran Singh in Bengaluru; Editing by Shailesh Kuber and Stephen Coates)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.83% 10016 Delayed Quote.15.42%
CSL LIMITED 2.91% 286.33 Delayed Quote.-4.33%
VIFOR PHARMA AG -0.28% 175.5 Delayed Quote.8.17%
All news about ASTRAZENECA PLC
01:26aTalks on second-gen COVID vaccine will take months and could fail, Valneva warns
RE
12:21aAstraZeneca Junks Ionis' Cholesterol Drug After Failing To Reach Efficacy Threshold In ..
MT
09/23ADRs End Lower, Alibaba and AstraZeneca Trade Actively
DJ
09/23Merck - LYNPARZA Approved in China as First-Line Maintenance Treatment with Bevacizumab..
AQ
09/23SECTOR UPDATE : Health Care Stocks Retreat Pre-Bell Friday
MT
09/23ETF PREVIEW : ETFs, Futures Plunge Pre-Bell Amid Global Central Bank Rate Decisions
MT
09/23SECTOR UPDATE : Health Care
MT
09/23AstraZeneca Gets European Commission Approval for Neuromuscular Disease Drug
MT
09/23Lynparza approved in China as 1st-line maintenance treatment with bevacizumab for HRD-p..
AQ
09/23Ionis Pharmaceuticals Says Hypercholesterolemia Drug Will Not Advance to Phase 3 After ..
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 44 322 M - -
Net income 2022 4 574 M - -
Net Debt 2022 24 523 M - -
P/E ratio 2022 38,8x
Yield 2022 2,70%
Capitalization 170 B 170 B -
EV / Sales 2022 4,38x
EV / Sales 2023 4,06x
Nbr of Employees 83 100
Free-Float 96,5%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 109,50 $
Average target price 142,05 $
Spread / Average Target 29,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC15.42%169 672
JOHNSON & JOHNSON-2.54%438 337
ELI LILLY AND COMPANY12.76%295 941
ROCHE HOLDING AG-18.41%259 291
ABBVIE INC.5.66%252 944
PFIZER, INC.-25.35%247 392